In summary, our results of both COL18A1 mRNA expression in publicly available BC data sets and ColXVIII protein expression in BC tissue and plasma samples in independent patient cohorts demonstrate the association of high ColXVIII levels with the severity of disease and reduced survival, and with HER2 and EGFR expression. This evidence concerns the gene ERBB2 and breast cancer.